BCG efficacy may be increased by ex vivo tumor antigen-loading and dendritic cell activation as BCG stimulated dendritic cells to secrete TNF-α, which is responsible for phenotypic and functional changes [57]. This evidence concerns the gene TNF and neoplasm.